BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 31638492)

  • 1. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes.
    Shi F; Wu M; Lian SS; Mo ZQ; Gou Q; Xu RD; Li HL; Huang ZM; Wu PH; Chen XM
    Radiology; 2019 Dec; 293(3):707-715. PubMed ID: 31638492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria.
    Shi F; Lian S; Mai Q; Mo Z; Zhuang W; Cui W; Shen L; Chen M; Wu P; Chen X
    Eur Radiol; 2020 May; 30(5):2454-2462. PubMed ID: 32002636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
    Li L; Xin Y; Zhang X; Chen Y; Yang Y; Zhou X; Ye F
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101878. PubMed ID: 35151909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria.
    Takuma Y; Takabatake H; Morimoto Y; Toshikuni N; Kayahara T; Makino Y; Yamamoto H
    Radiology; 2013 Dec; 269(3):927-37. PubMed ID: 24086071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma in the Caudate Lobe.
    Lee BC; Liu KL; Wu CH; Huang KW; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH; Liang PC
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1699-1707. PubMed ID: 29946941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
    Hsu CY; Huang YH; Chiou YY; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee FY; Lee SD
    Liver Transpl; 2011 May; 17(5):556-66. PubMed ID: 21506244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria.
    Liu PH; Lee YH; Hsu CY; Huang YH; Chiou YY; Lin HC; Huo TI
    Ann Surg Oncol; 2014 Nov; 21(12):3835-43. PubMed ID: 24903236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion.
    Wang YY; Wang LJ; Xu D; Liu M; Wang HW; Wang K; Zhu X; Xing BC
    HPB (Oxford); 2019 Apr; 21(4):425-433. PubMed ID: 30249510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemolipiodolization with or without embolization in transcatheter arterial chemoembolization combined with radiofrequency ablation for hepatocellular carcinoma-propensity score matching analysis.
    Shi F; Zhang L; Li S; Lin CJ; Shen LJ; Li CF; Jie M; Li ZW; Wu PH
    Oncotarget; 2016 May; 7(21):31311-21. PubMed ID: 27121318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis.
    Wang WD; Zhang LH; Ni JY; Jiang XY; Chen D; Chen YT; Sun HL; Luo JH; Xu LF
    Korean J Radiol; 2018; 19(4):613-622. PubMed ID: 29962868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.
    Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z
    J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
    Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
    J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.